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ABSTRACT
Glioblastoma recurrence involves the persistence of a subpopulation of cells with 
enhanced tumor-initiating capacity (TIC) that reside within the perivascular space, 
or niche (PVN). Anti-angiogenic therapies may prevent the formation of new PVN but 
have not prevented recurrence in clinical trials, suggesting they cannot abrogate TIC 
activity. We hypothesized that combining anti-angiogenic therapy with blockade of 
PVN function would have superior anti-tumor activity. We tested this hypothesis in an 
established intracranial xenograft model of GBM using a monoclonal antibody specific 
for murine and human VEGF (mcr84) and a Protein Epitope Mimetic (PEM) CXCR4 
antagonist, POL5551. When doses of POL5551 were increased to overcome an mcr84-
induced improvement in vascular barrier function, combinatorial therapy significantly 
inhibited intracranial tumor growth and improved survival. Anti-tumor activity was 
associated with significant changes in tumor cell proliferation and apoptosis, and a 
reduction in the numbers of perivascular cells expressing the TIC marker nestin. A 
direct effect on TICs was demonstrated for POL5551, but not mcr84, in three primary 
patient-derived GBM isolates. These findings indicate that targeting the structure and 
function of the PVN has superior anti-tumor effect and provide a strong rationale for 
clinical evaluation of POL5551 and Avastin in patients with GBM.
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INTRODUCTION
Glioblastoma (GBM) is the most common malignant 
brain tumor in adults and makes up approximately 5% of 
brain tumors in children [1]. Despite advances in surgery, 
radiation, and chemotherapy, the average survival for a 
patient with GBM remains just15 months from the time 
of diagnosis [2]. Temozolomide, an alkylating agent, is 
the only drug that, in combination with complete resection 
and radiation therapy, has been shown to improve overall 
survival [2, 3]. Alternate approaches, particularly those 
that can target the mechanisms of recurrence, are required.
Current models of GBM biology suggest that 
tumor recurrence depends upon the persistence of a 
subpopulation of cells with enhanced tumor-initiating 
capacity [4]. These so called tumor-initiating cells 
(TICs) or “tumor stem cells,” which are distinguished 
by their expression of stem cell markers and enhanced 
tumorigenicity, are purported to be a reservoir of germinal 
activity from which recurrent tumors derive [5, 6]. Similar 
to normal stem cell populations, GBM TICs reside within 
specialized niches [7, 8]. The perivascular space or niche 
(PVN) in GBM is a cellularly heterogeneous domain that 
is enriched with GBM TICs [9-12]. Within the PVN, 
functional interactions between GBM TICs microvascular 
endothelial cells, pericytes, astrocytes and microglia 
regulate TIC activity, mediate resistance to therapy 
and provide a conduit for invasion. Thus targeting the 
formation and function of the PVN has the potential to 
block GBM recurrence and improve cure. 
The formation of new PVN depends upon 
angiogenesis. GBM is renowned as being among the 
most angiogenic cancers, and this property is highly 
correlated with expression and secretion of vascular 
endothelial growth factor (VEGF) by tumor cells [13-15]. 
Blocking VEGF function with Bevacizumab (Avastin®), 
a humanized monoclonal antibody directed against 
VEGF-A, is approved for use in several cancers, and has 
accelerated approval for relapsed/refractory GBM [16, 
17]. Bevacizumab treatment frequently results in transient 
radiographic improvement and improved quality of life in 
patients with GBM [18]. However, despite initial response, 
nearly all patients progress, suggesting either resistance in 
angiogenic mechanisms or that tumor growth cannot be 
controlled by blocking angiogenesis and formation of new 
PVN alone[18].
Multiple cell types and signaling pathways mediate 
the functions of the PVN. We previously showed that 
endothelial cell-derived CXCL12 was required for 
localizing GBM cells to the PVN and also induced 
their growth [19]. CXCL12 and its receptor, CXCR4, 
are important for the functioning of multiple germinal 
matrices in a variety of tissues [20-22]. These functions 
have been successfully targeted in the clinical application 
of the CXCR4 antagonist AMD3100 for the mobilization 
of hematopoietic stem cells from their bone marrow niche 
and as an adjunct to chemotherapy [23-25]. In the central 
nervous system, the CXCL12-CXCR4 axis is critical for 
the function of the primary neurogenic subependymal zone 
as well as secondary germinal matrices in the cerebellum 
and hippocampus [26-28]. Disruption of this pathway 
by gene deletion results in significant abnormalities in 
hematopoiesis and brain development [28, 29]. 
CXCR4 expression is elevated in many brain tumor 
types, including GBM, where increased expression is 
associated with a worse prognosis [20, 30, 31]. CXCL12 
is also upregulated in the brain tumor microvasculature, 
and blocking the CXCR4 axis with antagonists AMD3100 
and AMD3465 resulted in significant anti-tumor effects in 
animal models [19, 20, 30-33]. In these studies both tumor 
cell and microvascular CXCR4 were identified as potential 
targets. These findings have supported the clinical 
evaluation of AMD3100 in the treatment of recurrent 
GBM, though efficacy has not been established. Here, we 
hypothesized that in GBM, CXCR4 antagonism works 
by blocking the TIC supportive effects of the PVN, and 
that in combination with VEGF antagonism, would exert 
superior anti-tumor effect by inhibiting PVN formation 
and function. We therefore performed a preclinical 
study of combined VEGF and CXCR4 antagonism in an 
intracranial xenograft model of GBM using the Protein 
Epitope Mimetic (PEM) CXCR4 antagonist POL5551 
[34], together with mcr89, an anti-VEGF antibody with 
dual functionality against both murine and human VEGF 
[35].
RESULTS
We previously demonstrated that CXCR4 
antagonism could disrupt the effects of endothelial cells 
on GBM cells in an in vitro model of the PVN and block 
intracranial xenograft growth [19, 32, 33]. Based on these 
findings, we were interested in determining whether 
there would be an advantage of combination therapy 
with a VEGF antagonist. POL5551, a novel CXCR4 
antagonist, was shown to produce superior bone marrow 
stem cell mobilization in mice compared to an established 
CXCR4 antagonist AMD3100 [34]. In this same study, 
AMD3100 also had greater dose-limiting toxicities. 
We hypothesized that the combination of POL5551 and 
mcr84 (VEGF inhibitor) would effectively target GBM 
PVN structure and function. We tested this hypothesis 
in an intracranial xenograft model of GBM using eGFP-
luciferase-expressing U87 cells. U87 xenografts are 
highly angiogenic and prior studies using them have 
identified tumor cell and microvascular targets for CXCR4 
antagonism [32, 36]. Thus, we used U87 xenografts to 
further define the cellular target(s) of CXCR4 inhibition. 
Animals bearing intracranial U87 xenografts that 
exhibited steady and equal growth over the two-week 
post-impantation period were randomly assigned to one 
of four different treatment groups: PBS and IgG (Control), 
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low dose POL5551 (LD-POL5551, 8mg/kg/day) and IgG, 
PBS and mcr84 (10mg/kg twice weekly), LD-POL5551 
and mcr84 (Figure 1). Mice were treated for a total of four 
weeks, and during the treatment period (week 2 to week 6) 
mcr84 alone or mcr84 in combination with LD-POL5551, 
significantly inhibited intracranial tumor growth to an 
equivalent level as measured by weekly BLI (Figure 2A). 
Tumor growth persisted after the cessation of treatment 
at 6 weeks. While the addition of POL5551 to mcr84 did 
not enhance the inhibition of tumor growth, analysis of 
survival indicated there was a benefit to the combination. 
Median survival was similar between control (18 days), 
mice treated with LD-POL5551 alone (17 days) or mice 
treated with mcr84 alone (18 days). However, mice treated 
with both LD-POL5551 and mcr84 exhibited significantly 
longer median survival (32 days) compared to control 
mice (p=0.0179) (Figure 2B). These results indicated 
possible synergy between the drugs. 
To further investigate interactions between 
POL5551 and mcr84, we measured compound levels in 
blood plasma, tumor–bearing cortex, and contralateral 
(non-tumor bearing) cortex. Consistent with an intact 
blood brain barrier (BBB) limiting brain permeation of 
POL5551, mean concentrations of POL5551 in normal 
brain tissue were 13-fold lower than in plasma (not 
shown). Compared to contralateral non-tumor bearing 
cortex, mean concentrations of POL5551 in the tumor bed 
were 1.7-fold higher (Figure 3A), indicating disruption of 
normal BBB function. Importantly, treatment with mcr84 
lowered the mean concentrations of POL5551 in tumor 
tissue and normal cortex by 28% and 42%, respectively. 
These findings suggested that, like Avastin®, mcr84 
might normalize and improve barrier function within the 
tumor vasculature [37, 38]. To determine whether the 
barrier effects of mcr84 could be extrapolated to other 
molecules, we examined the extravasation of albumin in 
tissue sections from control and mcr84 treated animals. 
Throughout tumor sections from mice treated with PBS 
and IgG control, we found albumin within the perivascular 
space (Figure 3B). mcr84 treatment markedly reduced the 
amount of albumin observed within the perivascular space 
indicating that VEGF antagonism results in improved 
BBB function. 
Decreased permeation of POL5551 in the setting 
of VEGF antagonism might reduce potential therapeutic 
efficacy. To test this hypothesis, we increased the 
POL5551 dose ten-fold and sought to determine whether 
this could overcome the permeation barrier and exert a 
superior anti-tumor effect. Four weeks of 80 mg/kg/day 
POL5551 (high dose (HD)) alone or in combination with 
mcr84 significantly inhibited intracranial xenograft growth 
(Figure 4A). Interestingly, upon cessation of therapy at 6 
weeks, tumor growth appeared to rebound in the mcr84-
containing regimens.
Figure 1: Treatment scheme. (A.) Engraftment of intracranial tumors was confirmed by serial BLI over the two week post implantation 
period. (B) A subcutaneous osmotic pump delivered either PBS or POL5551 (low dose or high dose) continuously over 28 days. Mice 
received either mcr84 or vehicle IgG antibody (10 mg/kg i.p. twice weekly for 4 weeks).
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Consistent with the inhibition of tumor growth, there 
was a significant increase in median survival from 18 to 
27 days in animals treated with the HD-POL5551 alone 
compared to control (p=0.024 (Figure 4B). The addition 
of mcr84 to HD-POL5551 further increased median 
survival to 35 days, which was a significant improvement 
compared to mcr84 (18 days) alone (p=0.009) (Figure 
4C). The difference in median survival between mcr84 
combined with low dose (32 days) and high dose (35 
days) POL5551 did not reach statistical significance but 
there was an apparent difference in overall survival. In the 
groups treated with the mcr84 and POL551 combination, 
there were no survivors by day 37 when LD-POL551 was 
used, whereas 30% survived beyond this timepoint HD-
POL5551was used. 
To determine whether the improved survival 
was associated with increased tumor tissue POL5551, 
we confirmed compound concentrations by mass 
spectrometry. At the higher dose of POL5551, mean 
concentrations were increased approximately 3-fold 
in tumor and non-tumor bearing (contralateral) cortex 
compared to animals receiving LD-POL5551 (Figure 4D). 
Importantly, tumor POL5551 concentrations following 
HD-POL5551 were not significantly decreased upon 
combination with mcr84. 
To evaluate the mechanism of HD-POL5551 anti-
tumor effects we performed tissue based analyses to 
examine tumor morphology, and tumor cell proliferation 
Figure 3: VEGF blockade with mcr84 enhances vascular barrier functions. (A) POL5551 concentrations in tumor tissue 
and non-tumor tissue from the contralateral cortex of xenograft bearing mice were determined by LC-MS/MS. POL5551 concentration 
was higher in tumor tissue versus non-tumor tissue. In both the tumor and non-tumor tissue, POL5551 concentration was decreased in the 
presence of mcr84. Bars represent the mean±SEM values. (B) mcr84 treatment markedly reduced the amount of albumin (red) detectable 
within the perivascular space of tumor sections compared to mice treated with vehicle control. Vascular endothelial cells were identified by 
endoglin staining (green) and nuclei are counterstained in blue with DAPI.
Figure 2: Combined mcr84 and LD-POL5551 blocks brain tumor growth and increases survival in vivo. (A) Tumor 
growth was measured by weekly BLI. Shown are the mean and SEM for weekly BLI measurements for each treatment group (n=13-18 
mice per group) normalized to fold over initial BLI. Arrows indicate the start and end of treatment. *p=0.0137 for the effect of treatment 
(weeks 2-6) on tumor growth (BLI). (B) LD-POL5551 in combination with mcr84 (n=13) increased median survival in comparison to 
vehicle controls (n=16) (p=0.0179). There were no significant improvements in survival for either of the monotherapy groups.
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and apoptosis. None of the treatments altered the 
characteristic non-infiltrative pattern of U87 growth 
(data not shown). As anticipated, treatment with 
mcr84 alone or in combination with HD-POL5551 
was associated with a decrease in endoglin positivity 
(Figure 5) which is indicative of decreased endothelial 
cell numbers. Proliferation was measured with Ki67 
immunofluorescence and apoptosis was measured by 
TUNEL staining. For both measurements, positivity 
was determined in a blinded fashion in multiple high-
powered fields from three separate subjects from each 
treatment group. All treatment regimens were associated 
with significant decreases in proliferation and increases 
in apoptosis compared to vehicle-treated controls as 
determined by two-tailed Fisher’s exact test (Table 1). 
In addition, treatment with HD-POL5551 alone or in 
combination with mcr84 had a widespread effect on 
the shape and size of tumor cell nuclei and appeared to 
reduce the numbers of nestin-positive perivascular cells 
(Figure 6A, asterisks). Nestin is an intermediate filament 
expressed by normal neural and brain tumor stem cells 
[39, 40]. It typically fills the cytoplasm of positive cells 
Table 1: Drug effects on proliferation and apoptosis in U87 tumors
Ki67 TUNEL
Treatment Group Fraction1 Pos Neg P-value2 Fraction Pos Neg P-value
PBS and IgG 0.28 567 1477 0.12 242 1793
PBS and mcr 0.24 443 1440 0.0027 0.14 297 1866 0.0794
POL and IgG 0.21 418 1593 0.0001 0.25 290 873 0.0001
POL and mcr 0.21 377 1392 0.0001 0.17 371 1792 0.0001
1Fraction of Ki67 positive or TUNEL positive cells was calculated as #positive cells/(#positive cells 
+ #negative cells) in multiple high-powered fields from three brains from each treatment group. 
2P values were calculated using a two-tailed Fisher’s exact test to compare treatment groups to 
control (PBS and IgG).
Figure 4: HD-POL5551 blocks brain tumor growth and increases survival in vivo. (A) Tumor growth was measured by 
weekly bioluminescence imaging. Shown are the mean and SEM for weekly BLI measurements each treatment group (n=7-18 mice per 
group). Arrows indicate the start and end of treatment. *p=0.0129 for the effect of treatment (weeks 2-6) on tumor growth (BLI). (B,C) HD-
POL5551 alone (n=7) and in combination with mcr84 (n=7) increased mean survival in comparison to vehicle controls (n=16) (p=0.014 
and p=0.009 respectively). (D) POL5551 concentrations in tumor tissue and non-tumor tissue from the contralateral cortex of xenograft 
bearing mice were determined by LC-MS/MS. POL5551 concentration was higher in tumor tissue versus non-tumor tissue. Bars represent 
the mean±SEM values. There was no significant decrease in tumor levels upon combination with mcr84. 
Oncotarget9816www.impactjournals.com/oncotarget
as seen in brains from PBS and IgG or PBS and mcr84 
treated animals. Interestingly, nestin positivity in tumors 
treated with HD-POL5551 was reduced to puncta (Figure 
6A, arrowheads). 
HD-POL5551 overcame the permeation barrier of 
VEGF antagonism and was associated with a superior 
anti-tumor effect and changes in tumor cell nuclear 
shape, proliferation and apoptosis compared to PBS 
controls (PBS+IgG and PBS+mcr84) (Table 1, Figure 
6). These findings support the literature that states 
CXCR4 antagonist targets are not limited to the vascular 
endothelium but include tumor cell targets as well [19, 
32]. Taken together with other reports describing a role for 
CXCR4 in the regulation of neural stem cell function [41, 
42] our data showing that POL5551 reduced the numbers 
of nestin positive perivascular cells, led us to hypothesize 
that POL5551 might have direct effects on tumor stem 
cells. To test this, and improve the translational relevance 
of these studies, we investigated the direct effects of 
POL5551 on three primary GBM isolates. 
The stem cell or TIC fraction of primary GBM 
isolates was measured as the CD133 positive fraction in 
tumorsphere cultures. CD133 positive cells in three low 
passage GBM preparations (CDI-2, CDI-5, B18) were 
isolated by MACs with antibody directed against CD133. 
To measure the effect of POL5551 on the TIC fraction, 
cells were treated with TSM with IgG (10 μg/mL) as 
vehicle control, POL5551 (1 μg/mL) and IgG, PBS and 
mcr84 (10 μg/mL), or POL5551 and mcr84 together. After 
treatment, the CD133 fraction was measured again and 
normalized to vehicle. mcr84 alone had no effect on the 
CD133 positive fraction. In contrast, POL5551 alone or 
in combination with mcr84 reduced the CD133 positive 
fraction to 70% of control values (Figure 6B). Together, 
these data indicate that CXCR4 antagonism reduces the 
GBM TIC fraction through direct action, requiring drug 
permeation into tumor tissue.
DISCUSSION
Despite decades of research, GBM remains among 
the most devastating malignancies. Targeting both the 
function and formation of the PVN could be important 
for preventing tumor growth, invasion, and metastasis. In 
this study, we showed that the combination of a CXCR4 
antagonist, POL5551, and a VEGF inhibitor, mcr84, can 
increase median overall survival in GBM xenografts 
Figure 5: Treatment with mcr84 reduces endoglin 
positivity. Tumor tissue from each of the treatment groups was 
evaluated for endoglin positive endothelial cells (green). mcr84 
alone or in combination with HD-POL5551 reduced the amount 
of endoglin positivity. HD-POL5551 had no effect on endoglin 
positivity. Scale bar equals 20 microns. 
Figure 6: HD-POL5551 reduces the GBM stem cell 
fraction in vivo and in vitro. (A) Tumor tissue from each 
of the treatment groups was evaluated for endoglin (brown) 
and nestin (purple) expression. Nuclei were counterstained 
with methyl green. In the PBS and IgG and PBS and mcr84 
groups, numerous nestin positive cells can be seen within the 
perivascular space (asterisks). In the HD-POL5551 and IgG and 
the HD-POL5551 and mcr84 groups, there are few to no nestin 
positive cells within the perivascular space. Nestin positivity is 
evident as punctate staining (arrowhead) rather than the usual 
diffuse cytoplasmic staining. Scale bar equals 20 microns. (B) 
CD133 fraction was measured by MACS in three different 
low passage isolates from GBM patients. Presented are the 
means and SEM of these measurements. * Indicates P<0.05 as 
determined by two-tailed t-test.
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compared to treatment with either drug as monotherapy. 
CXCR4 and VEGF are two of the few validated 
targets for directed GBM therapy. Bevacizumab, a 
humanized monoclonal antibody against VEGF-A, 
disrupts the formation of tumor growth by inhibiting 
angiogenesis; however, it does not improve cure. CXCR4 
expression is well known to be increased in many cancers, 
including GBM, and is associated with poor prognosis 
[43]. We showed that AMD3100 or AMD3465, related 
CXCR4 antagonists, inhibit the growth of intracranial 
GBM xenograft models by decreased proliferation 
and increased apoptosis of tumor cells [32, 33]. The 
CXCR4/CXCL12 pathway has also been shown to be 
involved in GBM invasiveness [30, 31]. AMD3100 is 
currently being evaluated in clinical trial in combination 
with bevacizumab for patients with high-grade gliomas 
(NCT01339039). In prior studies, sustained AMD3100 
treatment had significant side effects, including 
unexplained cardiotoxity [44]. By targeting formation and 
function of the tumor PVN, we hoped to decrease tumor 
growth and invasiveness synergistically and increase 
survival. POL5551 is thought to have less toxicity and 
has been shown to have superior ability to mobilize bone 
marrow stem cells in a mouse xenograft model [34]. The 
improved safety and efficacy of POL5551 over other 
CXCR4 antagonists makes it an attractive therapeutic 
candidate. 
POL5551 was first studied in xenografts for the 
use of stem cell mobilization at a dose of 8 mg/kg/day, 
prompting our initial dose for this experiment. We saw 
a significant increase in survival of mice treated with the 
combination of LD-POL5551 and mcr84 compared to 
vehicle or either drug alone, suggesting possible synergy. 
Measurement of tissue POL5551 concentrations revealed 
that in the presence of mcr84, POL5551 concentrations 
were decreased in normal brain as well as tumor tissue, 
suggesting mcr84 decreased blood vessel permeability and 
subsequent permeation of POL5551. VEGF was originally 
known as vascular permeability factor (VPF) because of 
its influence on the permeability of blood vessels [13]. 
Our results are consistent with several recent studies 
that showed VEGF antagonists, including bevacizumab, 
negatively affect concomitant drug penetration into tumor 
tissue [45-47].For this reason, we increased the dose 
of POL5551 by 10-fold which significantly increased 
POL5551 concentrations in plasma, tumor, and normal 
brain and significantly increased median survival. 
The association of higher POL5551 concentrations 
in tumor tissue with increased survival suggests that a 
critical target for POL5551 action is within the tumor 
parenchyma. This conclusion is supported by the apparent 
POL5551-induced decrease of nestin positive stem cells 
in vivo, and additionally by the reduction of the CD133 
positive cell fraction in three independent primary GBM 
isolates by POL5551 in our in vitro studies. Together, 
these studies strongly support the clinical evaluation 
of combined VEGF and CXCR4 antagonism, but with 
increased doses of the CXCR4 antagonist to overcome 
the improved vascular barrier function that results from 
effective VEGF antagonism. 
MATERIALS AND METHODS
Animals were used in accordance with an Animal 
Studies Protocol (# 20120174) approved by the Animal 
Studies Committee of the Washington University School 
of Medicine per the recommendations of the Guide for the 
Care and Use of Laboratory Animals (National Institutes 
of Health). 
Human Studies
Primary human GBM specimens for culture were 
obtained and utilized in accordance with a Washington 
University Institutional Review Board (IRB)-approved 
Human Studies Protocol (#201102299). 
Chemicals and other reagents
POL5551 was supplied by Polyphor and mcr84 was 
obtained from Affitech AS and purified in house by Protein 
A chromatography. All tissue culture reagents and media 
were obtained from Invitrogen unless otherwise indicated. 
Tumor cell lines
U87 cells were obtained from the American Type 
Culture Collection (Manassas, VA) and validated by them. 
Viral particles were produced by the Viral Vectors Core 
Facility of The Hope Center for Neurological Diseases at 
Washington University School of Medicine; expression 
vectors used in viral production contained a transgene 
for green fluorescent protein-firefly luciferase (GFP). 
GFP expressing cells were sorted and collected by high-
speed fluorescence-activated cell sorting (MoFlo High-
Performance Cell Sorter; DAKO). The eGFP-luciferase 
expressing U87 cells are simply referred to as U87 
cells in this study. Cells were cultured in alpha-MEM 
supplemented with 10% FBS (Biomedia, Foster City, CA) 
at 37o with 5% CO2. 
Primary Human GBM cells
Fresh brain tumor resection material from pediatric 
(CDI) or adult (B18) glioblastoma patients was obtained 
according to a Washington University School of Medicine 
IRB approved human studies protocol. Resection material 
was minced into small pieces using sterile scalpels and 
dissociated in Accutase at 37°C. Single cells were obtained 
and cultured in tumor sphere media (TSM), which 
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contains Neurobasal-A media (Gibco) supplemented with 
Glutamax (Gibco), 20 ng/mL epithelial growth factor 
(EGF, Sigma), 20 ng/mL basic fibroblastic growth factor 
(bFGF, Chemicon), 20 ng/mL leukemia inhibitory factor 
(LIF, Chemicon, 1 x N2 Supplement (Gibco), 1 x B-27 
Serum-Free Supplement (Gibco), and heparin (20 ug/mL, 
Sigma). Cells were initially plated on tissue-culture coated 
plates overnight to allow non-stem-like cells to attach, 
and the non-adherent stem-like cells were transferred to 
extracellular matrix protein (ECM)-coated tissue culture 
plates prepared by coating with 10% ECM (Sigma) in 
Hanks Buffered Saline Solution (HBSS) and washed three 
times in HBSS. Thereafter, GBM cells were maintained 
in adherent culture on ECM-coated plates in TSM media, 
which was changed every 2 to 3 days. 
In vitro drug treatments
Primary tumor cells were thawed, counted and equal 
numbers of cells were plated in ultra-low adherent 6 well 
plates in 2mls of regular TSM supplemented with 10 μg/
mL IgG (vehicle), or mcr84 alone (10μg/mL), POL5551 
(1μg/mL) and IgG, or POL5551 and mcr84 together. The 
CD133+ cell fractions were measured 72 hrs later using 
CD133 conjugated microbeads (Miltenyi Biotech) using 
manufacturer’s protocol. Briefly, tumorspheres were 
dissociated using trypsin and collagenase and incubated 
with FC blocking buffer and CD133 microbeads for 30 
min. The cells were washed in MACS buffer and loaded 
on to the MACS columns. The columns was washed three 
times, detached from the magnet and cells were eluted 
in TSM. Cell number was counted using trypan blue 
exclusion.
Generation of Intracranial xenografts
Intracranial xenografts were generated as previously 
described [32, 33]. In brief, 50,000 U87 cells in 7.5uL 
of PBS were injected into homozygous NCR nude mice 
(Taconic Farms, Germantown, NY) through a 27-gauge 
needle over 2 minutes at 2mm lateral and posterior to the 
bregma and 3mm below the dura. 
Bioluminescence imaging
Bioluminescence imaging (BLI) was performed as 
previously described [32, 33, 48]. Briefly, after injection 
with 150 ug/g D-luciferin (Biosynth) in PBS (i.p.), 
isoflurane-anesthetized mice were imaged with a charge-
coupled device camera-based BLI system (IVIS 50; 
Xenogen Corp., Alameda, CA; exposure time= 1-60 s, 
binning=8, field of view=12, f/stop=1, open filter). Signals 
were displayed as photons/s/cm2. Regions of interest were 
defined manually at 95% of the maximum pixel output 
using Living Image and IgorPro Software (v 2.50) and data 
were expressed as total photon flux (photons per second). 
Generally, the first mouse images were obtained 3-5 days 
following intracranial inoculation, then weekly. Data were 
analyzed and plotted as the ratio of bioluminescence on a 
given treatment day over bioluminescence on the first day. 
In vivo Drug Treatment
Mice were imaged two times after implantation of 
cells to identify those with equivalent tumor growth rates. 
Two weeks after tumor cell implantation, cohorts of mice 
with approximately equivalent tumor bioluminescence 
were divided into control and treatment groups (5-6 
mice per group per cohort). POL5551 was delivered as 
a continuous subcutaneous infusion. An osmotic pump 
(Alzet® model 2004, 28 day delivery) was inserted 
subcutaneously into each mouse and contained either PBS 
or POL5551 (8mg/kg or 80mg/kg). Prior to insertion, mice 
were anesthetized with ketamine hydrochloride at 150 mg/
kg and xylazine at 12 mg/kg (Phoenix Pharmaceuticals, 
St Joseph, MO) via i.p. injection. The incision was closed 
with Vetbond (3M, St. Paul, MN). mcr84 (10mg/kg [35]) 
or IgG antibody were injected i.p. twice weekly for 4 
weeks. 
Mice were euthanized per protocol if they exhibited 
weight loss of greater than 15% or displayed neurological 
symptoms. Blood samples were collected for plasma 
analysis. All mice were perfused with PBS; a subset 
was fixed with 4% paraformaldehyde. If fixed, brains 
were stored in paraformaldehyde for 24 hours, then 15% 
sucrose for 24 hours, then 30%-sucrose for 24 hours. 
Brains were embedded in OTC and stored at -80’C. 10-
12um sections were made for immunostaining. The brains 
of mice perfused only with PBS were frozen in liquid 
nitrogen then stored at -80’C. Tumor-bearing cortex and 
non-tumor-bearing (contralateral) cortex from these brains 
were further processed for determination of POL5551 
concentration.
Immunostaining
Sections (10um) were processed and analyzed as 
described 37. For endoglin/nestin colabeling studies, tissue 
sections were permeabilized with 0.025% Triton-X-100 
and endogenous peroxidase, and nonspecific binding 
sites were blocked as previously described [49]. Primary 
antibody concentrations were as follows: Endoglin (R&D 
systems AF1320, Goat, 1:200 dilution) and Nestin (Sigma 
N5413, rabbit, 1:200 dilution). Staining was detected 
using biotin-conjugated secondary antibodies augmented 
by streptavidin-horseradish peroxidase. Endoglin and 
Nestin were visualized using 3,3′-diaminobenzidine 
and the Vector VIP Peroxidase Substrate kit (DAKO), 
respectively. Sections were counterstained with methyl 
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green. Control sections were processed identically in the 
absence of primary antibody.
Endoglin/albumin colabeling, and TUNEL and Ki67 
staining was detected by immunofluorescence using the 
secondary AlexaFluor 555–conjugated and AlexaFluor 
488–conjugated secondary antibodies at a concentration 
of 1:1200 (Molecular Probes) for 90 minutes. Primary 
antibodies were as follows: albumin (Abcam Cat#: 
ab2406, rabbit polyclonal, 1:1000 dilution), Endoglin 
(R&D systems AF1320, Goat, 1:200 dilution), and Ki67 
(Thermo Scientific RM-9106-S0, Rabbit monoclonal, 
1:500 dilution.) Nuclei were counterstained with 
4′,6-diamidino-2-phenylindole (DAPI). Control sections 
were processed identically in the absence of primary 
antibody.
TUNEL staining was performed using the TACS 2 
TdT In situ Apoptosis Detection Kit (Trevigen Cat# 4810-
30-CK) per manufacturer’s instructions. Briefly, tissue 
sections were treated with 5ug/ml proteinase K, followed 
by incubation in labeling reaction mix (Tdt dNTP Mix, 
TdT Enzyme, Mn2+ , and 1XTdT labeling Buffer, for 
60 minutes at 37°C in humidified chamber, followed by 
incubation with the 1X Tdt Stop Buffer. Sections were 
washed in 1X PBS and incubated in AlexaFluor 568–
conjugated secondary antibody (1:1500) (Molecular 
Probes) for 90 minutes. Nuclei were counterstained with 
4′,6-diamidino-2-phenylindole (DAPI). Control sections 
were processed identically in the absence of Tdt Enzyme. 
POL5551 concentration
Pretreatment plasma samples and plasma, brain 
and tumor tissue from the time of death were obtained 
and stored at -20C. Samples were processed by Polyphor 
by mass spectrometry analysis. Concentrations of 
POL5551 in plasma and brain were determined using a 
high pressure liquid chromatography coupled to mass 
spectrometry detection (LC-MS/MS analytical method). 
Briefly, after addition of an internal standard, plasma 
and brain homogenate samples (aliquot of 50 µL) were 
extracted with acetonitrile (acidified with formic acid). 
Supernatants were evaporated to dryness under a stream of 
nitrogen, and reconstituted in H2O/ ACN, 95/5, v/v, +0.2% 
formic acid. Extracts were then analyzed by reverse-phase 
chromatography (Acquity BEH C18 column, 100 x 2.1 
mm, 1.7 µm column), using an acidified water /acetonitrile 
gradient elution (UPLC, Waters). The detection and 
quantification was performed by mass spectrometry, with 
electrospray interface in positive mode and selective 
fragmentation of analytes (AB Sciex 4000 Q Trap mass 
spectrometer). Standards, Quality Controls and samples 
were extracted and assayed in the same manner.
Statistical analysis
Data were analyzed using GraphPad Prism version 
4.00 (GraphPad Software). Kaplan-Meier survival 
curves were analyzed using pairwise log-rank tests. 
Statistical differences in tumor growth curves (measured 
by bioluminescence) were analyzed using two-way 
ANOVA. The effect of drug treatments on proliferation 
and apoptosis were evaluated by two-tailed Fisher’s exact 
test. The effects of drug treatments on stem cell fraction 
were evaluated by two-tailed t-test.
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